Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosensors launches BioMatrix Flex stent; trial data positive

This article was originally published in Clinica

Executive Summary

Biosensors International has launched its BioMatrix Flex drug-eluting stent in Europe, the Middle East, Africa and Asia. The Singapore-based company CE marked BioMatrix Flex for a range of indications, including ST elevated myocardial infarction, acute coronary syndromes and diabetes mellitus, in January (www.clinica.co.uk, 25 January 2010). The device is coated with an abluminal biodegradable polymer and the limus drug Biolimus A9.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094917

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel